Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (74)
  2. Journal Article (20)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (1)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (108)
  2. Hematologic Malignancies, Division of (108)
  3. Center for Hematologic Malignancies (68)
  4. Lymphoma (58)
  5. Survivorship Research (45)
  6. Sloan Kettering Institute Postdocs (42)

More Groups

People
  1. Andrew Zelenetz (50)
  2. Gilles Salles (48)
  3. Anita Kumar (46)
  4. Maria Palomba (45)
  5. Ariela Noy (43)
  6. Alison Moskowitz (40)

More People

Years
  1. 2025 (5)
  2. 2024 (17)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. American Journal of Hematology (4)

More Publications

Publishers
  1. American Society of Hematology (50)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (7)
  5. Ferrata Storti Foundation (4)
  6. John Wiley & Sons (4)

More Publishers

Results (108)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R(2)) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leslie, L. A.; Belada, D.; Kopeckova, K.; Offner, F.; Brody, J.; Canales, M.; García-Sancho, A. M.; Nijland, M.; Andersson, P. O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update
    Meeting Abstract

    Falchi, L.; Abrisqueta, P.; Nijland, M.; Leppä, S.; Hutchings, M.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; de Vos, S.; Cheah, C. Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab + R-DHAX/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: Updated phase 1/2 results
    Meeting Abstract

    Abrisqueta, P.; Cordoba, R.; Falchi, L.; de Vos, S.; Nijland, M.; Offner, F.; Wu, J.; Bykhovski, I.; Wang, L.; Rana, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Patel, K.; Hertzberg, M.; Falchi, L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features
    Correspondence

    Zibara, V.; Sen, F.; Scordo, M.; Falchi, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update
    Meeting Abstract

    Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results
    Meeting Abstract

    Abrisqueta, P.; Falchi, L.; Phillips, T. J.; De Vos, S.; Nijland, M.; Offner, F.; Bykhovski, I.; Wu, J.; Wang, L.; Rana, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab combined with R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: Phase 1/2 update
    Meeting Abstract

    Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save